The effect of adding nebulized low molecular weight heparin to the treatment of outpatients with Covid 19

?Comparison of the effect of adding nebulized low molecular weight heparin to the treatment of patients with Covid 19 who are treated with Remdesivir on an outpatient basis compared to the usual treatment during five days

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231008059655N1

Enrollment

Registered

2023-11-06

Start date

2023-11-11

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group:Patients with covid 19 are treated with the appropriate dose of remdesivir (Ronak Pharmaceutical Company) (The first day with a dose of 200 mg and the second, third,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Positive Covid-19 test Patients who are treated on an outpatient basis

Exclusion criteria

Exclusion criteria: Patients with poor general condition and hospitalization in the emergency room Patients with acute medical problems

Design outcomes

Primary

Measure	Time frame
Peak expiratory flow rate. Timepoint: In this study, the time periods of measuring the peak expiratory flow rate will be measured on days 1, 2, 3, 4 and 5 after receiving the drug. Method of measurement: Peak flow meter.;Saturation O2. Timepoint: In this study, the time periods of measuring oxygen saturation are measured on days 1, 2, 3, 4 and 5 after receiving the drug. Method of measurement: Pulse oximeter.	—

Measure

Time frame

Peak expiratory flow rate. Timepoint: In this study, the time periods of measuring the peak expiratory flow rate will be measured on days 1, 2, 3, 4 and 5 after receiving the drug. Method of measurement: Peak flow meter.;Saturation O2. Timepoint: In this study, the time periods of measuring oxygen saturation are measured on days 1, 2, 3, 4 and 5 after receiving the drug. Method of measurement: Pulse oximeter.

—

Secondary

Measure	Time frame
Respiratory rate. Timepoint: In this study, the time periods of measuring respiratory rate are measured on days 1, 2, 3, 4 and 5 after receiving the drug. Method of measurement: Number of breaths per minute.;Pulse rate. Timepoint: In this study, the time periods of measuring pulse rate are measured on days 1, 2, 3, 4 and 5 after receiving the drug. Method of measurement: The number of heartbeats per minute.	—

Measure

Time frame

Respiratory rate. Timepoint: In this study, the time periods of measuring respiratory rate are measured on days 1, 2, 3, 4 and 5 after receiving the drug. Method of measurement: Number of breaths per minute.;Pulse rate. Timepoint: In this study, the time periods of measuring pulse rate are measured on days 1, 2, 3, 4 and 5 after receiving the drug. Method of measurement: The number of heartbeats per minute.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Vefagh nematollahi

Ahvaz University of Medical Sciences

Shiri.t@ajums.ac.ir+98 61 3292 3985

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026